Costimulation blockade in autoimmunity and transplantation

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 2, 2008, Pages 299-306

  Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

abatacept; autoimmune disease; belatacept; Costimulation; organ transplantation; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BASILIXIMAB; BELATACEPT; CD28 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FK 734; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY CD28; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; PLACEBO; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; AUTOIMMUNE DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; KIDNEY FUNCTION; MONOTHERAPY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIGENS, CD28; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; TRANSPLANTATION IMMUNOLOGY;

EID: 38949173232     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.01.002     Document Type: Review

References (41)

1. Bretscher P.A. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 96 (1999) 185-190
2. Sayegh M.H., and Turka L.A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338 (1998) 1813-1821
3. Linsley P.S., and Ledbetter J.A. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11 (1993) 191-212
4. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4-Ig. N Engl J Med 349 (2003) 1907-1915
5. Genovese M., Becker J.-C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005) 1114-1123
6. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 (2005) 770-781
7. Judge T.A., Tang A., Spain L.M., Deans-Gratiot J., Sayegh M.H., and Turka L.A. The in vivo mechanism of action of CTLA4-Ig. J Immunol 156 (1996) 2294-2299
8. Webb L.M., Walmsley M.J., and Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 26 (1996) 2320-2328
9. Lenschow D.J., Zeng Y., Thistlethwaite J.R., Montag A., Brady W., Gibson M.G., et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4 Ig. Science 257 (1992) 789-792
10. Pearson T.C., Alexander D.Z., Winn K.J., Linsley P.S., Lowry R.P., and Larsen C.P. Transplantation tolerance induced by CTLA4-Ig. Transplantation 57 (1994) 1701-1706
11. Vincenti F. Chronic induction: what's new in the pipeline. Contrib Nephrol 146 (2005) 22-29
12. Van Parijs L., and Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280 (1998) 243-248
13. Yamada A., Salama A.D., and Sayegh M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 13 (2002) 559-575
14. Alegre M.L., Frauwirth K.A., and Thompson C.B. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1 (2001) 220-228
15. McAdam A.J., Schweitzer A.N., and Sharpe A.H. The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 165 (1998) 231-247
16. Kim K.S., Denton M.D., Chandraker A., Knoflach A., Milord R., Waaga A.M., et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol 158 (2001) 977-986
17. Vanhove B., Laflamme G., Coulon F., Mougin M., Vusio P., Haspot F., et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 102 (2003) 564-570
18. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006) 1018-1028
19. Shiao S.L., McNiff J.M., Masunaga T., Tamura K., Kubo K., and Pober J.S. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and agonistic activities. Transplantation 83 (2007) 304-313
20. Larsen C.P., Pearson T.C., Adams A.B., Tso P., Shirasugi N., Strobertm E., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5 (2005) 443-453
21. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S.., et al. CTLA4-Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103 (1999) 1243-1252
22. Finck B.K., Linsley P.S., and Wofsy D. Treatment of murine lupus with CTLA4-Ig. Science 265 (1994) 1225-1227
23. Sidiropoulos P., Bertsias G., Kritikos H.D., Kouroumali H., Voudouris K., and Boumpas D.T. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 63 (2004) 144-148
24. Kremer J.M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 2263-2271
25. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144 (2006) 865-876
26. Westhovens R., Emery P., and Aranda R. Abatacept provides sustained clinical benefit through 3 years in rheumatoid arthritis patients with inadequate responses to methotrexate. [abstract SAT0203]. Ann Rheum Dis 65 suppl II (2006) 512
27. Genant H.K., Peterfy C., and Wu C. An ACR 20 response is not required for inhibition of structural damage progression by abatacept: results from the AIM Trial. [abstract 1991]. Arthritis Rheum 52 suppl 9 (2005) S350
28. Weinblatt M.E., Combe B., Covucci A., Aranda R., Becker J.C., Keystone E., et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Res 54 (2006) 2807-2816
29. Meier-Kriesche H.-U., Schold J.D., Srinivas T.R., and Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Amer J Transplantation 4 (2004) 378-383
30. Ojo A.O., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931-940
31. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Chapman J.R., and Allen R.D. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78 (2004) 557-565
32. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338 (1998) 161-165
33. Vincenti F., Ramos E., Brattstrom C., Cho S., Ekberg H., and Grinyo J. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71 (2001) 1282-1287
34. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 351 (2004) 2715-2729
35. Kirk A.D., Harlan D.M., Armstrong N.N., Davis T.A., Dong Y., Gray G.S., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 94 (1997) 8789-8794
36. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 14 (1996) 233-258
37. Linsley P.S., Greene J.K., Brady W., Bajorath J., Ledbetter J.A., Peach R., et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1 (1994) 793-801
38. Lenschow D.J., Zeng Y., Hathcock K.S., Zuckerman L.A., Freeman G., Thistlethwaite J.R., et al. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 60 (1995) 1171-1178
39. Hariharan S., McBride M.A., Cherikh W.S., Tolleris C.B., Bresnahan B.A., and Johnson C.P. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62 (2002) 311-318
40. Vincenti F, Larsen C, Muhlbacher F, Mark D, Wang Y, Listman J, et al. 2007. Interim report of phase 2 long-term safety of belatacept [abstract 0253]. Presented at European Society of Organ Transplantation; September 29-October 3, 2007; Prague, Czech Republic.
41. Krinzman S.J., De Sanctis G.T., Cernadas M., Mark D., Wang Y., Listman J., et al. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J Clin Invest 98 (1996) 2693-2699